Unexplained hyperglycemia in continuous subcutaneous insulin infusion: Evaluation and treatment

Diabetes Educator

Volumn 34, Issue 2, 2008, Pages 327-333

  Ponder, Stephen W ^a,b,c   Skyler, Jay S ^d   Kruger, Davida F ^e   Matheson, Della ^d   Brown, Bruce W ^f  

^a Children's Diabetes and Endocrine Center of South Texas   (United States)

^b TEXAS A M COLLEGE OF MEDICINE   (United States)

^c DRISCOLL CHILDREN S HOSPITAL   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e HENRY FORD HOSPITAL   (United States)

^f ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; INSULIN;

ARTICLE; AWARENESS; BLOOD; CLASSIFICATION; DIABETIC KETOACIDOSIS; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INDWELLING CATHETER; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION;

AWARENESS; BLOOD GLUCOSE; CATHETERS, INDWELLING; DIABETES MELLITUS, TYPE 1; DIABETIC KETOACIDOSIS; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS;

EID: 41549123610     PISSN: 01457217     EISSN: 15546063     Source Type: Journal    
DOI: 10.1177/0145721708315682     Document Type: Article

References (31)

1. Renner R., Pfutzner A., Trautman, Harzer O., Sauter K., Landgraf R. Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Diabetes Care. 1999 ; 22: 784-788.
2. Boland EA, Grey M., Oesterie A., Frederickson L., Tamborlane WV Continuous subcutaneous insulin infusion. Diabetes Care. 1999 ; 22: 1779-1784.
3. Raskin P., Stowig SM Benefits of insulin pump therapy. In: Fredrickson L, ed. The Insulin Pump Therapy Book: insights From the Experts. Sylmar, CA: Mini-Med Technologies; 1995: 10-19.
4. Pickup J., Mattock M., Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomized clinical trials. BMJ. 2002 ; 324: 1-6.
5. Pickup J., Keen H. Continuous subcutaneous insulin infusion at 25 years. Diabetes Care. 2002 ; 25: 593-598.
6. Lenhard MJ, Reeves GD Continuous subcutaneous insulin infusion. Arch Intern Med. 2001 ; 161: 2293-2300.
7. Narayan KMV, Boyle JP, Thompson TJ, Sorenson SW Lifetime risk for diabetes in the United States. JAMA. 2003 ; 290: 1884-1890.
8. www.geocities.com/Vienna/Strass/5726/hhsfunding
9. Kanakis SJ, Watts C., Leichter SB The business of insulin pumps in diabetes care: clinical and economic considerations. Clin Diabetes. 2002 ; 20: 214-216.
10. Herman WH, Ilag LL, Johnson SL, et al. A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with diabetes. Diabetes Care. 2005 ; 28: 1568-1573.
11. Gentili P., Maldonsto A., Bloise D., Burla F., Coronel G., DiPaolantonin T. Personality variables and compliance with insulin therapy in type 2 diabetic subjects. Diabetes Nutr Metab. 2000 ; 13: 1-6.
12. Wainstein J., Metzger M., Boaz M., et al. Insulin pump therapy vs. multiple daily injections in obese type 2 diabetic patients already receiving two or more daily injections plus metformin. Diabetes Med. 2005 ; 22: 1037-1046.
13. Mecklenburg RS, Guinn TS, Sannar CA, et al. Malfunctions of continuous subcutaneous insulin infusion systems: a one-year prospective study of 127 patients. Diabetes Care. 1984 ; 9: 351-355.
14. Novo Nordisk-Center for Online Professional Continuing Education. 2007. Available at: www.Novonordisk.com.
15. Saudek CD Novel forms of insulin delivery. Endocrinol Metab Clin North Am. 1997 ; 26: 599-610.
16. Bode B., Strange P. Efficacy, safety and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes. Diabetes Care. 2001 ; 24: 69-72.
17. Brackenridge B., D'Almeida B., Frederickson L., et al. The Pump Trainer's Manual. Sylmar, CA: Mini-Med Technologies ; 1994.
18. Mecklenburg RS, Benson EA, Benson JW, et al. Acute complications associated with insulin pump therapy: report of experience 161 patients. JAMA. 1984 ; 8: 268-273.
19. Wolpert HA, Faradji RN, Bonner-Weir S., Lipes MA Metabolic decompensation in pump users due to lispro insulin precipitation. BMJ. 2002 ; 324: 1253.
20. Bode B., Weinstein R., Bell D., et al. Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion. Diabetes Care. 2002 ; 25: 439-444.
21. Raskin R., Holcombe JH, Tamborlane WV, et al. A comparison of insulin lispro and buffered regular human insulin administered via continuous subcutaneous insulin infusion pump. J Diabetes Complications. 2001 ; 15: 295-300.
22. Humalog™ (insulin lispro) [package insert]. Indianapolis, IN: Eli Lilly and Company ; 2004.
23. Novolog™ (insulin aspart) [package insert]. Princeton, NJ: Novo Nordisk ; 2001.
24. Apidra™ (insulin glulisine) [package insert]. Kansas City, MO: Aventis Pharmaceuticals ; 2004.
25. Plank J., Siebenhofer A., Berghold A., et al. Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus. Arch Intern Med. 2005 ; 165: 1337-1344.
26. Plank J., Wutte A., Brunner G., et al. A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes. Diabetes Care. 2002 ; 25: 2053-2057.
27. Rademecker RP, Scheen AJ Continuous subcutaneous insulin infusion with short-acting insulin analogues or human regular insulin: efficacy, safety, quality of life and cost effectiveness. Diabetes Metab Res Rev. 2004 ; 20: 178-188.
28. Reichel A., Rietzsch H., Kohler HJ, et al. Cessation of insulin infusion at night-time during CSII therapy: comparison of results of human regular insulin and insulin lispro. Exp Clin Endocrinol Diabetes. 1998 ; 106: 168-172.
29. Attia N., Jones TW, Holcombe J., Tamborlane WV Comparison of regular human insulin and insulin lispro after interruption of continuous subcutaneous insulin infusion and treatment of acutely decompensated IDDM. Diabetes Care. 1998 ; 21: 817-821.
30. Guerci B., Meyer I., Salle A., et al. Comparison of metabolic deterioration between insulin analogs and regular insulin after a 5-hour interruption of CSII in type 1 patients. J Clin Endocrinol Metab. 1999 ; 84: 2673-2678.
31. DeFelippies MR, Bell MA, Heyob JA, Storms SM In vitro stability of insulin lispro in continuous subcutaneous insulin infusion. Diabetes Technol Ther. 2006 ; 8: 358-368.